CN102625808B - 螺环酰胺衍生物 - Google Patents
螺环酰胺衍生物 Download PDFInfo
- Publication number
- CN102625808B CN102625808B CN201080043822.8A CN201080043822A CN102625808B CN 102625808 B CN102625808 B CN 102625808B CN 201080043822 A CN201080043822 A CN 201080043822A CN 102625808 B CN102625808 B CN 102625808B
- Authority
- CN
- China
- Prior art keywords
- formula
- ethyl
- mixture
- stirred
- yield
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(c(*)c(c(*)c1*)O)c1N Chemical compound *c(c(*)c(c(*)c1*)O)c1N 0.000 description 7
- DLNSDCXWYDQHQY-UHFFFAOYSA-N CC(C(N(C)CC1(CCN(Cc2cc(CCO)ccc2F)CC1)N)=O)(F)F Chemical compound CC(C(N(C)CC1(CCN(Cc2cc(CCO)ccc2F)CC1)N)=O)(F)F DLNSDCXWYDQHQY-UHFFFAOYSA-N 0.000 description 1
- YSWMZOFFUQUCGL-UHFFFAOYSA-N CC(C)(C)OC(N(CCc(c(OC1)c2NC1=O)ccc2O[Si+](C)(C)C(C)(C)C)CCN(C1CCCCC1)C(CCOCCc1cc(CN(CC2)CCC22OCCNC2)ccc1)=O)=O Chemical compound CC(C)(C)OC(N(CCc(c(OC1)c2NC1=O)ccc2O[Si+](C)(C)C(C)(C)C)CCN(C1CCCCC1)C(CCOCCc1cc(CN(CC2)CCC22OCCNC2)ccc1)=O)=O YSWMZOFFUQUCGL-UHFFFAOYSA-N 0.000 description 1
- GELCNJDITWBJJG-UHFFFAOYSA-N CC(C)Cc1nc(C(O)=O)c[s]1 Chemical compound CC(C)Cc1nc(C(O)=O)c[s]1 GELCNJDITWBJJG-UHFFFAOYSA-N 0.000 description 1
- FUJWQGZPBSWGPX-UHFFFAOYSA-N CC(C)NCC(OC)OC Chemical compound CC(C)NCC(OC)OC FUJWQGZPBSWGPX-UHFFFAOYSA-N 0.000 description 1
- KICKJQXTBMXLQC-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4c[s]c(CCO)c4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4c[s]c(CCO)c4)CC3)OCC2)=O)c[s]1 KICKJQXTBMXLQC-UHFFFAOYSA-N 0.000 description 1
- IKRHMDGSOOLLEZ-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4c[s]c(CCOC(C)=O)c4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4c[s]c(CCOC(C)=O)c4)CC3)OCC2)=O)c[s]1 IKRHMDGSOOLLEZ-UHFFFAOYSA-N 0.000 description 1
- NATWMGQJWWHMLA-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6N)C5CCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6N)C5CCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 NATWMGQJWWHMLA-UHFFFAOYSA-N 0.000 description 1
- ZPSOWNAEIWQQOA-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6O)Cc5ccccc5)=O)ccc4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6O)Cc5ccccc5)=O)ccc4)CC3)OCC2)=O)c[s]1 ZPSOWNAEIWQQOA-UHFFFAOYSA-N 0.000 description 1
- YJQGUIJQCSQJEW-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(OC(C)(C)C)=O)ccc4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4cc(CCOCCC(OC(C)(C)C)=O)ccc4)CC3)OCC2)=O)c[s]1 YJQGUIJQCSQJEW-UHFFFAOYSA-N 0.000 description 1
- HRTMAOYBWIJLJP-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4ccc(CCOCCC(O)=O)cc4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4ccc(CCOCCC(O)=O)cc4)CC3)OCC2)=O)c[s]1 HRTMAOYBWIJLJP-UHFFFAOYSA-N 0.000 description 1
- AEMIDHSMBUFJIZ-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(CCc4cccc(CCOCCC(O)=O)c4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(CCc4cccc(CCOCCC(O)=O)c4)CC3)OCC2)=O)c[s]1 AEMIDHSMBUFJIZ-UHFFFAOYSA-N 0.000 description 1
- SCOHVIWSLZMAFR-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(Cc4c(C)c(CCOCCC(N(CCNCCc(ccc(O)c5N6)c5OCC6=O)C5CCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(Cc4c(C)c(CCOCCC(N(CCNCCc(ccc(O)c5N6)c5OCC6=O)C5CCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 SCOHVIWSLZMAFR-UHFFFAOYSA-N 0.000 description 1
- QDLPQRSSBFWKTI-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCN(Cc4cccc(CCOCCC(N(CCNCCc(ccc(O)c5N6)c5OCC6=O)CCOC)=O)c4Cl)CC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCN(Cc4cccc(CCOCCC(N(CCNCCc(ccc(O)c5N6)c5OCC6=O)CCOC)=O)c4Cl)CC3)OCC2)=O)c[s]1 QDLPQRSSBFWKTI-UHFFFAOYSA-N 0.000 description 1
- JTUIRONQUPEAHX-UHFFFAOYSA-N CC(C)c1nc(C(N2CC3(CCNCC3)OCC2)=O)c[s]1 Chemical compound CC(C)c1nc(C(N2CC3(CCNCC3)OCC2)=O)c[s]1 JTUIRONQUPEAHX-UHFFFAOYSA-N 0.000 description 1
- WUXYAXICRPFTQV-UHFFFAOYSA-N CCCC(CCC)N(CC(OC)OC)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1F)=O Chemical compound CCCC(CCC)N(CC(OC)OC)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1F)=O WUXYAXICRPFTQV-UHFFFAOYSA-N 0.000 description 1
- ARZVJGISJVTCDV-UHFFFAOYSA-N CCCCN(CCNCCc(c(OC1)c2NC1=O)ccc2O)C(CCOCCc1cc(C)cc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1)=O Chemical compound CCCCN(CCNCCc(c(OC1)c2NC1=O)ccc2O)C(CCOCCc1cc(C)cc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1)=O ARZVJGISJVTCDV-UHFFFAOYSA-N 0.000 description 1
- DODIMYLWMFPPAZ-UHFFFAOYSA-N CCCCN(CCNCCc(ccc(O)c1N2)c1OCC2=O)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(CC)n2)=O)c1Cl)=O Chemical compound CCCCN(CCNCCc(ccc(O)c1N2)c1OCC2=O)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(CC)n2)=O)c1Cl)=O DODIMYLWMFPPAZ-UHFFFAOYSA-N 0.000 description 1
- FAGPKOIXURMHEE-UHFFFAOYSA-N CCN(CCNCCc(c(OC1)c2NC1=O)ccc2O)C(CCOCCc1cc(CCN(C2)CC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)ccc1)=O Chemical compound CCN(CCNCCc(c(OC1)c2NC1=O)ccc2O)C(CCOCCc1cc(CCN(C2)CC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)ccc1)=O FAGPKOIXURMHEE-UHFFFAOYSA-N 0.000 description 1
- VZBYAMOCCWMNBM-UHFFFAOYSA-N CCN(CCNCCc(c(S1)c2NC1=O)ccc2O)C(CCOCCc(cc1)ccc1OCCCN(CC1)CCC1(C1)OCCN1C(c1c[s]c(C(C)C)n1)=O)=O Chemical compound CCN(CCNCCc(c(S1)c2NC1=O)ccc2O)C(CCOCCc(cc1)ccc1OCCCN(CC1)CCC1(C1)OCCN1C(c1c[s]c(C(C)C)n1)=O)=O VZBYAMOCCWMNBM-UHFFFAOYSA-N 0.000 description 1
- ODRJCJOILPPSOL-UHFFFAOYSA-N CCN(CCNCCc(c(S1)c2NC1=O)ccc2O)C(CCOCCc(cccc1CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1F)=O Chemical compound CCN(CCNCCc(c(S1)c2NC1=O)ccc2O)C(CCOCCc(cccc1CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1F)=O ODRJCJOILPPSOL-UHFFFAOYSA-N 0.000 description 1
- FSFAYVJRVPZXMS-UHFFFAOYSA-N CCN(CCNCCc(ccc(O)c1N2)c1SC2=O)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1Cl)=O Chemical compound CCN(CCNCCc(ccc(O)c1N2)c1SC2=O)C(CCOCCc1cccc(CN(CC2)CCC2(C2)OCCN2C(c2c[s]c(C(C)C)n2)=O)c1Cl)=O FSFAYVJRVPZXMS-UHFFFAOYSA-N 0.000 description 1
- VKIJFZGAAPOULL-UHFFFAOYSA-N CCOC(CCSc1cc(C(O)=O)ccc1)=O Chemical compound CCOC(CCSc1cc(C(O)=O)ccc1)=O VKIJFZGAAPOULL-UHFFFAOYSA-N 0.000 description 1
- PQQNHKAXAXCFFX-UHFFFAOYSA-N CCc1nc(C(N2CC3(CCN(CCc4ccc(CCOCCC(N(CCCCCO)CCNCCc(ccc(O)c5N6)c5SC6=O)=O)cc4)CC3)OCC2)=O)c[s]1 Chemical compound CCc1nc(C(N2CC3(CCN(CCc4ccc(CCOCCC(N(CCCCCO)CCNCCc(ccc(O)c5N6)c5SC6=O)=O)cc4)CC3)OCC2)=O)c[s]1 PQQNHKAXAXCFFX-UHFFFAOYSA-N 0.000 description 1
- SDUZFUDOIIIRKV-UHFFFAOYSA-N CCc1nc(C(N2CC3(CCN(Cc(cccc4CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6O)C5CCCC5)=O)c4Cl)CC3)OCC2)=O)c[s]1 Chemical compound CCc1nc(C(N2CC3(CCN(Cc(cccc4CCOCCC(N(CCNCCc(c(OC5)c6NC5=O)ccc6O)C5CCCC5)=O)c4Cl)CC3)OCC2)=O)c[s]1 SDUZFUDOIIIRKV-UHFFFAOYSA-N 0.000 description 1
- HDCBVJHRCMNNMJ-UHFFFAOYSA-N COC(CNCCCCCCO)OC Chemical compound COC(CNCCCCCCO)OC HDCBVJHRCMNNMJ-UHFFFAOYSA-N 0.000 description 1
- PSZFZCGXUXOTHO-UHFFFAOYSA-N Cc(c(C=C=[O]C)ccc1)c1Br Chemical compound Cc(c(C=C=[O]C)ccc1)c1Br PSZFZCGXUXOTHO-UHFFFAOYSA-N 0.000 description 1
- BJVKXVYPUHSJDA-UHFFFAOYSA-N Cc1nc(C(N2CC3(CCN(Cc4cc(CCOCCC(N(CC(OC)OC)C5CCCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 Chemical compound Cc1nc(C(N2CC3(CCN(Cc4cc(CCOCCC(N(CC(OC)OC)C5CCCCC5)=O)ccc4)CC3)OCC2)=O)c[s]1 BJVKXVYPUHSJDA-UHFFFAOYSA-N 0.000 description 1
- MGXDXHWAXXHMKQ-UHFFFAOYSA-N Nc(c(C=C1)c2NC1=O)ccc2O Chemical compound Nc(c(C=C1)c2NC1=O)ccc2O MGXDXHWAXXHMKQ-UHFFFAOYSA-N 0.000 description 1
- BZJDLWPACCCSNT-UHFFFAOYSA-N Nc(c(S1)c2NC1=O)ccc2O Chemical compound Nc(c(S1)c2NC1=O)ccc2O BZJDLWPACCCSNT-UHFFFAOYSA-N 0.000 description 1
- YMYROQRUHMUXMM-UHFFFAOYSA-N Nc(ccc(O)c1N2)c1OCC2=O Chemical compound Nc(ccc(O)c1N2)c1OCC2=O YMYROQRUHMUXMM-UHFFFAOYSA-N 0.000 description 1
- FIIOBSFCUXUVJO-UHFFFAOYSA-N OCCc(cccc1CO)c1I Chemical compound OCCc(cccc1CO)c1I FIIOBSFCUXUVJO-UHFFFAOYSA-N 0.000 description 1
- VYHWVNIIGCLAKX-UHFFFAOYSA-N OCCc1cccc(C=O)c1Cl Chemical compound OCCc1cccc(C=O)c1Cl VYHWVNIIGCLAKX-UHFFFAOYSA-N 0.000 description 1
- ZHVUSRVRYMHWBW-UHFFFAOYSA-N OCc1cccc(C#CCO)c1 Chemical compound OCc1cccc(C#CCO)c1 ZHVUSRVRYMHWBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0913342.2A GB0913342D0 (en) | 2009-07-31 | 2009-07-31 | Compounds - 801 |
| GB0913342.2 | 2009-07-31 | ||
| PCT/GB2010/051242 WO2011012896A2 (en) | 2009-07-31 | 2010-07-29 | Compounds - 801 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102625808A CN102625808A (zh) | 2012-08-01 |
| CN102625808B true CN102625808B (zh) | 2014-08-27 |
Family
ID=41129405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080043822.8A Expired - Fee Related CN102625808B (zh) | 2009-07-31 | 2010-07-29 | 螺环酰胺衍生物 |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2713322C (en) | 2008-02-06 | 2017-01-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and their use in the treatment of pulmonary disorders |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
| GB201021992D0 (en) * | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) * | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| WO2016179349A1 (en) * | 2015-05-05 | 2016-11-10 | Northwestern University | Cxcr4 chemokine receptor modulators |
| CN109195975B (zh) * | 2016-09-30 | 2022-01-04 | 四川海思科制药有限公司 | 一种二氮杂螺[5.5]十一碳烷衍生物及其用途 |
| ES2836113T3 (es) | 2016-12-14 | 2021-06-24 | Beijing Showby Pharmaceutical Co Ltd | Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario |
| US10501449B2 (en) | 2017-06-01 | 2019-12-10 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
| EP3682906A1 (en) * | 2019-01-17 | 2020-07-22 | Julius-Maximilians-Universität Würzburg | Compound targeting norepinephrine transporter |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008096127A2 (en) * | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators |
| WO2009098448A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | Compounds |
| CN101553231A (zh) * | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| CN101636379A (zh) * | 2006-12-20 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | 胺衍生物及其在β2肾上腺素受体介导的疾病中的用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2707186A (en) | 1954-05-06 | 1955-04-26 | Hoffmann La Roche | Imidazolone derivatives |
| AU565621B2 (en) | 1983-04-26 | 1987-09-24 | Smithkline Beckman Corporation | Dopaminergic carbostyrils |
| FR2665440B1 (fr) | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| PL194689B1 (pl) | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania |
| GB9604578D0 (en) | 1996-03-04 | 1996-05-01 | Sericol Ltd | Photocurable compositions |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
| WO2002008213A1 (en) | 2000-07-07 | 2002-01-31 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
| CN1255391C (zh) | 2000-07-07 | 2006-05-10 | 安吉奥金尼药品有限公司 | 作为血管破坏剂的colchinol衍生物 |
| ES2329586T3 (es) * | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| PT1751131E (pt) | 2004-03-10 | 2009-02-13 | Janssen Pharmaceutica Nv | Aril-piperidinas ou aril-piperazinas substituídas com heterociclos de 5 membros inibidoras de mtp |
| WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| US20050215542A1 (en) | 2004-03-23 | 2005-09-29 | Pfizer Inc | Compounds for the treatment of diseases |
| DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| DE102004045648A1 (de) | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP2008516939A (ja) | 2004-10-15 | 2008-05-22 | アストラゼネカ アクチボラグ | 化学化合物 |
| WO2006051373A1 (en) | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
| DE102005007654A1 (de) | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| ATE516026T1 (de) | 2005-02-21 | 2011-07-15 | Shionogi & Co | Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung |
| TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| ES2407115T3 (es) * | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| GB0613154D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
| GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
-
2009
- 2009-07-31 GB GBGB0913342.2A patent/GB0913342D0/en not_active Ceased
-
2010
- 2010-07-29 MY MYPI2012000429A patent/MY163117A/en unknown
- 2010-07-29 TR TR2018/19140T patent/TR201819140T4/tr unknown
- 2010-07-29 JP JP2012522254A patent/JP5612092B2/ja not_active Expired - Fee Related
- 2010-07-29 ES ES10752118T patent/ES2702467T3/es active Active
- 2010-07-29 SG SG2012002358A patent/SG177634A1/en unknown
- 2010-07-29 KR KR1020127005165A patent/KR101664525B1/ko not_active Expired - Fee Related
- 2010-07-29 EA EA201290077A patent/EA020566B1/ru not_active IP Right Cessation
- 2010-07-29 AU AU2010277384A patent/AU2010277384B2/en not_active Ceased
- 2010-07-29 CN CN201080043822.8A patent/CN102625808B/zh not_active Expired - Fee Related
- 2010-07-29 MX MX2012001232A patent/MX2012001232A/es active IP Right Grant
- 2010-07-29 PE PE2012000138A patent/PE20121441A1/es active IP Right Grant
- 2010-07-29 UA UAA201200405A patent/UA106887C2/uk unknown
- 2010-07-29 BR BR112012008043-1A patent/BR112012008043A2/pt not_active Application Discontinuation
- 2010-07-29 NZ NZ597589A patent/NZ597589A/en not_active IP Right Cessation
- 2010-07-29 CU CU2012000021A patent/CU24103B1/es active IP Right Grant
- 2010-07-29 CA CA2768527A patent/CA2768527C/en not_active Expired - Fee Related
- 2010-07-29 WO PCT/GB2010/051242 patent/WO2011012896A2/en not_active Ceased
- 2010-07-29 EP EP10752118.9A patent/EP2459572B1/en active Active
- 2010-07-30 TW TW099125331A patent/TWI443103B/zh not_active IP Right Cessation
- 2010-07-30 UY UY0001032814A patent/UY32814A/es not_active Application Discontinuation
- 2010-07-30 US US12/847,000 patent/US8455483B2/en not_active Expired - Fee Related
- 2010-07-30 AR ARP100102795A patent/AR080601A1/es active IP Right Grant
- 2010-07-31 SA SA110310628A patent/SA110310628B1/ar unknown
-
2012
- 2012-01-12 CO CO12004253A patent/CO6491034A2/es active IP Right Grant
- 2012-01-16 IL IL217557A patent/IL217557A/en active IP Right Grant
- 2012-01-31 CL CL2012000263A patent/CL2012000263A1/es unknown
- 2012-01-31 CR CR20120054A patent/CR20120054A/es unknown
- 2012-01-31 GT GT201200028A patent/GT201200028A/es unknown
- 2012-01-31 DO DO2012000032A patent/DOP2012000032A/es unknown
- 2012-01-31 NI NI201200018A patent/NI201200018A/es unknown
- 2012-01-31 HN HN2012000217A patent/HN2012000217A/es unknown
- 2012-02-28 ZA ZA2012/01473A patent/ZA201201473B/en unknown
- 2012-09-14 US US13/617,978 patent/US8476265B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101553231A (zh) * | 2006-08-15 | 2009-10-07 | 弗特克斯药品有限公司 | 毒蕈碱受体调节剂 |
| CN101636379A (zh) * | 2006-12-20 | 2010-01-27 | 阿斯利康(瑞典)有限公司 | 胺衍生物及其在β2肾上腺素受体介导的疾病中的用途 |
| WO2008096127A2 (en) * | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators |
| WO2009098448A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | Compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4934223B2 (ja) | 化合物 | |
| CN102625808B (zh) | 螺环酰胺衍生物 | |
| JP2009530272A (ja) | ベータ２アドレナリン作動性受容体アゴニストとしてのベンゾチアゾール誘導体 | |
| MX2008001664A (es) | Derivados novedosos de benzotiazolona. | |
| HK1171755B (en) | Spirocyclic amide derivatives | |
| HK1158196A (zh) | 化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1171755 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1171755 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20210729 |